Morris, Manning & Martin, LLP

In 2010, more than $3 billion in penalties were paid under the False Claims Act alone. The numbers are staggering.  The threat of individual liability looms ever larger with recent prosecutions making headlines.  These and numerous other developments have conspired to create a period of unprecedented turbulence and uncertainty for counsel and executives charged with preventing and defending against accusations of fraud and abuse in pharmaceutical drug sales and marketing.  Between ever-larger recoveries made under the False Claims Act, continued prosecution and exclusion of executives through the Park Doctrine, and increasingly contradictory court opinions on off-label drug marketing, it is more important than ever to receive expert guidance to traverse an increasingly vague regulatory landscape.

On March 27-28, MMM's Holly Pierson will join a prestigious faculty at the American Conference Institute’s 12th National Forum on Fraud and Abuse in the Sale and Marketing of Drugs to examine the changing regulatory landscape and offer real-world solutions for attendees.  Held at the New York Marriott Downtown, this conference is the industry-leading conference uniting respected practitioners, top prosecutors, and leading in-house counsel and compliance executives.  Featuring in-depth analysis of landmark cases involving individual liability for executives and in-house counsel, detailed discussions of the Foreign Corrupt Practices Act, useful guidance on the new aggregate spend reporting requirements, and analysis of critical federal appellate and Supreme Court opinions, this event will leave attendees with a specific plan of action for combating fraud allegations.

Ms. Pierson will speak on a panel titled "Best Practices for Complying with Corporate Integrity Agreements (CIAs)."  Other topics at the conference include:

• Avoiding Individual Accountability: How to Steer Clear of Prosecution and Exclusion Under the Responsible Corporate Officer Doctrine
• Light at the End of the Tunnel? Recent Court Cases and the Saga of Off-Label Promotion Enforcement
• Analyzing the Broadened Use of the False Claims Act (FCA) and Its Implications for Pharma
• Pharma and The Social Network: Methods for Utilizing Social Media to Promote Pharmaceuticals Under Existing Regulations and Expert Discussion on the Eventual FDA Guidelines
• Designing and Implementing Effective Compliance Programs to Minimize Litigation and Reputation Risks
• Government Spotlight: Identifying Federal and State Enforcement Priorities
• Addressing and Overcoming Kickback Allegations in Dealings with Clinicians and Other Healthcare Professionals
• Implementing a Training and Monitoring Program to Minimize the Inherent Risks Accompanying a Sales Force in the Field

To learn more about the conference or to register, please visit ACI's web site or download a copy of the conference brochure.